Follow us for updates
© 2020
Read the Story →

China's Sinovac Vaccine is Cleared for Emergency Use in Philippines

Third to receive emergency authorization.
by Arianne Merez
Just now
Photo/s: Shutterstock

The COVID-19 vaccine from China's Sinovac has been granted emergency use authorization in the Philippines, the Food and Drug Administration said Monday, paving the way for its local use.

The development makes Sinovac's COVID-19 vaccine the third to receive emergency use authorization in the Philippines after Pfizer's and AstraZeneca's jabs.

"The FDA is granting an emergency use authorization to the COVID-19 vaccine of Sinovac," FDA Director General Eric Domingo said.

"It is decided that all conditions for an EUA are present and that the benefit of using the vaccine outweighs the known and potential risks," he added.


Pfizer Vaccine Gets First Ever Emergency Use Authority in Philippines

AstraZeneca Vaccine Gets Emergency Use Authorization in Philippines

Explained: How COVID Vaccines Get Fast-Tracked for Emergency Use

Granting an EUA to a vaccine would expedite its availability to the people who need it the most. In the case of the COVID-19 pandemic, the Philippine government is rushing to make vaccines available to the most vulnerable to the virus: medical frontliners, and the elderly.

Continue reading below ↓

CoronaVac, the COVID-19 vaccine produced by Sinovac has been found to be 91.25% effective in trials in Turkey but other, more robust trials in Brazil only demonstrated an efficacy rate of around 50%.

Domingo said the use of Sinovac's vaccine is not recommended for healthcare workers as it has an efficacy of 50.4% in this group.

The FDA however recommends its use for "clinically healthy individuals aged 18-59 years old."

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.